Stephen E Bottoms
Overview
Explore the profile of Stephen E Bottoms including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
335
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Manunta M, McAnulty R, McDowell A, Jin J, Ridout D, Fleming J, et al.
Am J Respir Cell Mol Biol
. 2013 Apr;
49(3):471-80.
PMID: 23614789
Receptor-targeted nanocomplexes are nonviral vectors developed for gene delivery to the airway epithelium for the treatment of pulmonary disease associated with cystic fibrosis. The present study aimed to optimize the...
2.
Manunta M, McAnulty R, Tagalakis A, Bottoms S, Campbell F, Hailes H, et al.
PLoS One
. 2011 Nov;
6(10):e26768.
PMID: 22046351
Background: Gene therapy mediated by synthetic vectors may provide opportunities for new treatments for cystic fibrosis (CF) via aerosolisation. Vectors for CF must transfect the airway epithelium efficiently and not...
3.
Bottoms S, Howell J, Reinhardt A, Evans I, McAnulty R
PLoS One
. 2010 Mar;
5(3):e9674.
PMID: 20300191
The TGF-beta family of mediators are thought to play important roles in the regulation of inflammation and airway remodelling in asthma. All three mammalian isoforms of TGF-beta, TGF-beta(1-3), are expressed...
4.
Maher T, Evans I, Bottoms S, Mercer P, Thorley A, Nicholson A, et al.
Am J Respir Crit Care Med
. 2010 Mar;
182(1):73-82.
PMID: 20203246
Rationale: Patients with idiopathic pulmonary fibrosis (IPF), a progressive disease with a dismal prognosis, exhibit an unexplained disparity of increased alveolar epithelial cell (AEC) apoptosis but reduced fibroblast apoptosis. Objectives:...
5.
Tagalakis A, McAnulty R, Devaney J, Bottoms S, Wong J, Elbs M, et al.
Mol Ther
. 2008 Apr;
16(5):907-15.
PMID: 18388925
Synthetic vectors for cystic fibrosis (CF) gene therapy are required that efficiently and safely transfect airway epithelial cells, rather than alveolar epithelial cells or macrophages, and that are nonimmunogenic, thus...
6.
Yuste J, Botto M, Bottoms S, Brown J
PLoS Pathog
. 2007 Sep;
3(9):1208-19.
PMID: 17845072
The physiological functions of the acute phase protein serum amyloid P (SAP) component are not well defined, although they are likely to be important, as no natural state of SAP...
7.
Reinhardt A, Bottoms S, Laurent G, McAnulty R
Respir Res
. 2005 Apr;
6:30.
PMID: 15819978
Background: Sub-epithelial extracellular matrix deposition is a feature of asthmatic airway remodelling associated with severity of disease, decline in lung function and airway hyperresponsiveness. The composition of, and mechanisms leading...
8.
Hodges R, Gisli Jenkins R, Wheeler-Jones C, Copeman D, Bottoms S, Bellingan G, et al.
Am J Pathol
. 2004 Oct;
165(5):1663-76.
PMID: 15509536
Levels of prostaglandin E(2) (PGE(2)), a potent inhibitor of fibroblast function, are decreased in the lungs of patients with pulmonary fibrosis, which has been shown to be because of limited...
9.
Reinhardt A, Bottoms S, Laurent G, McAnulty R
Chest
. 2003 Mar;
123(3 Suppl):428S.
PMID: 12629017
No abstract available.